Cargando…

Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated Clostridioides difficile Infection Among Patients with Lung Cancer

AIM: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs)-associated Clostridioides difficile infection (CDI) among lung cancer patients have been reported in case reports and adverse events reporting system databases in the United States and Japan, but clinical data remained insuf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Ying-Shan, Lin, Yu-Ching, Hung, Ming-Szu, Ho, Meng-Chin, Fang, Yu-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805707/ https://www.ncbi.nlm.nih.gov/pubmed/36597497 http://dx.doi.org/10.2147/OTT.S386807

Ejemplares similares

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
por: Ho, Meng-Chin, et al.
Publicado: (2022)

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases
por: Lee, Hsin-Hua, et al.
Publicado: (2019)

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
por: Huang, Allen Chung-Cheng, et al.
Publicado: (2021)

Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection
por: Lee, Ching-Chi, et al.
Publicado: (2021)

Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Chen, Chien-Hung, et al.
Publicado: (2019)

Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro
por: Chiu, Hsin-Yi, et al.
Publicado: (2020)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook
por: Miles, Brittany, et al.
Publicado: (2021)

Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma
por: Zhang, Chao, et al.
Publicado: (2018)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

Editorial: Microbial interactions of Clostridioides difficile
por: Goh, Shan, et al.
Publicado: (2023)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection
por: Mohammad, Al Wahadneh, et al.
Publicado: (2023)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
por: Wu, Shang-Gin, et al.
Publicado: (2019)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
por: Qiao, Xiaojuan, et al.
Publicado: (2015)

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
por: Zhang, Haijun
Publicado: (2016)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2022)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer
por: Hung, Ming-Szu, et al.
Publicado: (2016)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018)

Impacts of Corticosteroid Therapy at Acute Stage of Hospital-Onset Clostridioides difficile Infections
por: Lee, Ching-Chi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kacbng9shdn7ipgtn60i6olgiv